FRANCALANCI, MICHELA
FRANCALANCI, MICHELA
Scienze della Salute (DSS)
A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells
2008 A. Lombardi; G. Cantini; E. Piscitelli; S. Gelmini; M. Francalanci; T. Mello; E. Ceni; G. Varano; G. Forti; M. Rotondi; A. Galli; M. Serio; M. Luconi
DISSECTING THE ORIGIN OF INDUCIBLE BROWN FAT IN ADULT HUMANS THROUGH A NOVEL ADIPOSE STEM CELL MODEL FROM ADIPOSE TISSUE SURROUNDING PHEOCHROMOCYTOMA
2014 Di Franco A; Guasti D; Mazzanti B; Ercolino T; Francalanci M; Nesi G; Bani D; Forti G; Mannelli M; Valeri A; Luconi M
Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell
2012 Baglioni S; Cantini G; Poli G; Francalanci M; Squecco R; Di Franco A; Borgogni E; Frontera S; Nesi G; Liotta F; Lucchese M; Perigli G; Francini F; Forti G; Serio M; Luconi M
Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism.
2010 Cantini G; Lombardi A; Borgogni E; Francalanci M; Ceni E; Degl'Innocenti S; Gelmini S; Poli G; Galli A; Serio M; Forti G; Luconi M.
Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model.
2010 Luconi M; Mangoni M; Gelmini S; Poli G; Nesi G; Francalanci M; Pratesi N;Cantini G; Lombardi A; Pepi M; Ercolino T; Serio M; Orlando C; Mannelli M.
Stimulated expression of CXCL12 in adrenocortical carcinoma by the ppargamma ligand rosiglitazone impairs cancer progression
2021 Cantini G.; Fei L.; Canu L.; Lazzeri E.; Sottili M.; Francalanci M.; Angelotti M.L.; De Filpo G.; Ercolino T.; Gelmini S.; Mangoni M.; Nesi G.; Hantel C.; Mannelli M.; Maggi M.; Luconi M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells | 2008 | A. Lombardi; G. Cantini; E. Piscitelli; S. Gelmini; M. Francalanci; T. Mello; E. Ceni; G. Varano; G. Forti; M. Rotondi; A. Galli; M. Serio; M. Luconi | |
| DISSECTING THE ORIGIN OF INDUCIBLE BROWN FAT IN ADULT HUMANS THROUGH A NOVEL ADIPOSE STEM CELL MODEL FROM ADIPOSE TISSUE SURROUNDING PHEOCHROMOCYTOMA | 2014 | Di Franco A; Guasti D; Mazzanti B; Ercolino T; Francalanci M; Nesi G; Bani D; Forti G; Mannelli M; Valeri A; Luconi M | |
| Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell | 2012 | Baglioni S; Cantini G; Poli G; Francalanci M; Squecco R; Di Franco A; Borgogni E; Frontera S; Nesi G; Liotta F; Lucchese M; Perigli G; Francini F; Forti G; Serio M; Luconi M | |
| Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism. | 2010 | Cantini G; Lombardi A; Borgogni E; Francalanci M; Ceni E; Degl'Innocenti S; Gelmini S; Poli G; Galli A; Serio M; Forti G; Luconi M. | |
| Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. | 2010 | Luconi M; Mangoni M; Gelmini S; Poli G; Nesi G; Francalanci M; Pratesi N;Cantini G; Lombardi A; Pepi M; Ercolino T; Serio M; Orlando C; Mannelli M. | |
| Stimulated expression of CXCL12 in adrenocortical carcinoma by the ppargamma ligand rosiglitazone impairs cancer progression | 2021 | Cantini G.; Fei L.; Canu L.; Lazzeri E.; Sottili M.; Francalanci M.; Angelotti M.L.; De Filpo G.; Ercolino T.; Gelmini S.; Mangoni M.; Nesi G.; Hantel C.; Mannelli M.; Maggi M.; Luconi M. |